Parmax Pharma Limited has filed its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The certificate confirms adherence to regulatory requirements for the dematerialization process during Q4 FY26.

Regulatory Compliance Certificate

The company submitted the mandatory certificate to BSE Limited on April 17, 2026, as required under the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. Managing Director Umang Gosalia (DIN: 05153830) digitally signed the certificate, confirming compliance with prescribed timelines and procedures.

The certificate validates that all securities received for dematerialization during the quarter were immediately mutilated and cancelled after due verification. The depository's name was substituted in the company's records as the registered owner within the prescribed timelines from receipt of the security certificate.

Registrar Confirmation

Purva Sharegistry (India) Pvt. Ltd., the company's Registrar and Share Transfer Agent (RTA), provided confirmation supporting the quarterly certificate. The RTA holds SEBI registration number INR000001112 as a Category 1 Registrar for IPO and Share Transfer services.

Compliance Officer Ms. Deepali Gaonkar from Purva Sharegistry confirmed that security certificates received for dematerialization were properly processed and that the securities are listed on stock exchanges where earlier issued securities are listed.

Dematerialization Details

The quarter witnessed dematerialization activity involving specific share certificates. The company processed dematerialization requests within the regulatory framework, ensuring proper documentation and timeline adherence.

The dematerialization involved two certificates of 100 shares each, both processed on January 23, 2026. Certificate number 0019483 covered distinctive numbers 3135301 to 3135400, while certificate number 0019484 covered distinctive numbers 3135401 to 3135500.

Compliance Framework

The quarterly certificate filing demonstrates the company's commitment to maintaining regulatory compliance under SEBI guidelines. The process ensures transparency in share transfer operations and maintains accurate records of ownership changes through the depository system.

The certification process involves coordination between the company, its RTA, and depositories to ensure seamless dematerialization while maintaining regulatory standards. This quarterly filing represents part of the ongoing compliance requirements for listed companies under SEBI regulations.

Parmax Pharma Limited has announced the appointment of Ms. Bhakti Aghera as Company Secretary and Compliance Officer, marking a key addition to the company's management team. The appointment was formalized through a regulatory filing with BSE Limited on March 25, 2026.

Board Approval and Regulatory Compliance

The Board of Directors approved Ms. Aghera's appointment during their meeting held on March 25, 2026, acting on the recommendation of the Nomination and Remuneration Committee. The appointment is effective from March 25, 2026, and has been communicated to BSE Limited in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

Professional Background

Ms. Bhakti Aghera brings substantial expertise to her new role as an associate member of The Institute of Company Secretaries of India. She possesses six years of knowledge and experience in corporate legal and secretarial services. Notably, she has previously worked with Parmax Pharma Limited, providing her with valuable familiarity with the company's operations and regulatory requirements.

Regulatory Framework

The appointment follows the prescribed regulatory framework under Regulation 30 read with Para A(7) of Part A of Schedule III of the Listing Regulations. The company has also complied with SEBI circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, ensuring all required disclosures for changes in Key Managerial Personnel are properly documented and communicated to the stock exchange.